Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Opens Door to Broad Dealmaking in RNAi

This article was originally published in Start Up

Executive Summary

Novartis has seemingly changed the RNAi therapeutics game with its potential blockbuster deal with Alnylam, suggesting that getting to the bottom of RNAi's therapeutic possibilities requires significant assets and staying power.

You may also be interested in...



Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus

With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.

Sanofi Moves into MicroRNA, Signs Preclinical Platform Deal with Regulus

With $25 million upfront, $10 million in equity and hundreds of millions of dollars in possible milestones, Sanofi makes a significant early bet on the latest RNA-based therapeutic class to emerge.

Isis: Pondering Platform Power

The January 2008 collaboration Isis forged with Genzyme was transformative for Isis and a desperately sought-after validation of the antisense field. But unlike its brethren in oligonucleotide drug development -- and most biotechs, for that matter -- Isis rejects the notion of commercializing its products. The deal sets up a paradox: Can Isis remain a platform company once investors' focus is on a product and its trajectory? In a sense, can it stay small?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091160

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel